clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Szántó D et al. [Could Helicobacter pylori cause reactive arthro-osteitis?]. 1997 Orv Hetil pmid:9340585
Rodrigues AD and Wong SL Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. 1997 Adv. Pharmacol. pmid:9342173
Yasui N et al. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. 1997 Int Clin Psychopharmacol pmid:9347384
Pendland SL et al. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. 1997 J. Clin. Microbiol. pmid:9350781
Lévy M et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. 1997 Gastrointest. Endosc. pmid:9351036
Laine L et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9354200
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Breuer T et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. 1997 Aliment. Pharmacol. Ther. pmid:9354204
Wurzer H et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. 1997 Aliment. Pharmacol. Ther. pmid:9354205
Harris A H. pylori eradication by LAC. 1997 Aliment. Pharmacol. Ther. pmid:9354216
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Jablonowski H et al. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients. 1997 Drugs pmid:9358196
Grosset J and Ji B Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. 1997 Drugs pmid:9358197
Dubé MP et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. 1997 J. Infect. Dis. pmid:9359722
Zuberi BF et al. Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer. 1997 J Pak Med Assoc pmid:9361485
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Ramirez Mayans JA et al. [Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin]. 1996 Acta Gastroenterol. Latinoam. pmid:9363265
Buckley MJ et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. 1997 Dig. Dis. Sci. pmid:9365144
Hultén K et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. 1997 Antimicrob. Agents Chemother. pmid:9371366
Tartaglione T Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. 1997 Jul-Aug Clin Ther pmid:9377608
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
Stephenson GA et al. Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. 1997 J Pharm Sci pmid:9383733
Anzueto A et al. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. 1997 Sep-Oct Clin Ther pmid:9385486
Suzuki Y et al. [Antimicrobial activities of clarithromycin against recent obtained clinical isolates]. 1997 Jpn J Antibiot pmid:9394238
Ando H et al. [Changes in serum anti-Helicobacter pylori IgG antibody, pepsinogen I, and pepsinogen II after eradication therapy of Helicobacter pylori]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9396326
Riff DS et al. Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report. 1996 Helicobacter pmid:9398874
Harford W et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. 1996 Helicobacter pmid:9398875
Schwartz H et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. 1996 Helicobacter pmid:9398876
Jaup BK Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin. 1996 Helicobacter pmid:9398878
Moayyedi P et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. 1996 Helicobacter pmid:9398880
Mégraud F and Malfertheiner P Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995. 1996 Helicobacter pmid:9398889
O'Morain C et al. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. 1996 Helicobacter pmid:9398893
Lind T et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. 1996 Helicobacter pmid:9398894
van der Hulst RW et al. Treatment of Helicobacter pylori infection: a review of the world literature. 1996 Helicobacter pmid:9398908
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Martin SJ et al. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. 1997 Diagn. Microbiol. Infect. Dis. pmid:9401809
Sander P et al. The role of ribosomal RNAs in macrolide resistance. 1997 Mol. Microbiol. pmid:9402018
Barry AL et al. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9405952
Greco S et al. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. 1997 Ann Pharmacother pmid:9416400
Shafran SD et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. 1998 J. Infect. Dis. pmid:9419201
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Pipkin GA et al. Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review. 1997 Helicobacter pmid:9421117
Tompkins DS et al. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. 1997 Helicobacter pmid:9421121
Hultén K et al. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. 1997 Helicobacter pmid:9421122
O'Connor HJ et al. One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? 1997 Helicobacter pmid:9421124
Matsunaga K et al. [Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy]. 1997 Gan To Kagaku Ryoho pmid:9422074
Midolo PD et al. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. 1997 Pathology pmid:9423225